C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 320—Bioavailability and Bioequivalence RequirementsSubpart B—Procedures for Determining the Bioavailability or Bioequivalence of Drug Products

21 C.F.R. § 320.22 (2026)

Criteria for waiver of evidence of in vivo bioavailability or bioequivalence

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1979–2013 15citing cases
At a glance

Courts have cited this section in 15 opinions since 1979. The most litigated part is subsection (b) (1 case).

(a) Any person submitting a full or abbreviated new drug application, or a supplemental application proposing any of the changes set forth in § 320.21(c), may request FDA to waive the requirement for the submission of evidence measuring the in vivo bioavailability or demonstrating the in vivo bioequivalence of the drug product that is the subject of the application. An applicant shall submit a request for waiver with the application. Except as provided in paragraph (f) of this section, FDA shall waive the requirement for the submission of evidence of in vivo bioavailability or bioequivalence if the drug product meets any of the provisions of paragraphs (b), (c), (d), or (e) of this section.

(b) For certain drug products, the in vivo bioavailability or bioequivalence of the drug product may be self-evident. FDA shall waive the requirement for the submission of evidence obtained in vivo measuring the bioavailability or demonstrating the bioequivalence of these drug products. A drug product's in vivo bioavailability or bioequivalence may be considered self-evident based on other data in the application if the product meets one of the following criteria:

(1) The drug product:

(i) Is a parenteral solution intended solely for administration by injection, or an ophthalmic or otic solution; and

(ii) Contains the same active and inactive ingredients in the same concentration as a drug product that is the subject of an approved full new drug application or abbreviated new drug application.

(2) The drug product:

(i) Is administered by inhalation as a gas, e.g., a medicinal or an inhalation anesthetic; and

(ii) Contains an active ingredient in the same dosage form as a drug product that is the subject of an approved full new drug application or abbreviated new drug application.

(3) The drug product:

(i) Is a solution for application to the skin, an oral solution, elixir, syrup, tincture, a solution for aerosolization or nebulization, a nasal solution, or similar other solubilized form; and

(ii) Contains an active drug ingredient in the same concentration and dosage form as a drug product that is the subject of an approved full new drug application or abbreviated new drug application; and

(iii) Contains no inactive ingredient or other change in formulation from the drug product that is the subject of the approved full new drug application or abbreviated new drug application that may significantly affect absorption of the active drug ingredient or active moiety for products that are systemically absorbed, or that may significantly affect systemic or local availability for products intended to act locally.

(c) FDA shall waive the requirement for the submission of evidence measuring the in vivo bioavailability or demonstrating the in vivo bioequivalence of a solid oral dosage form (other than a delayed release or extended release dosage form) of a drug product determined to be effective for at least one indication in a Drug Efficacy Study Implementation notice or which is identical, related, or similar to such a drug product under § 310.6 of this chapter unless FDA has evaluated the drug product under the criteria set forth in § 320.33, included the drug product in the Approved Drug Products with Therapeutic Equivalence Evaluations List, and rated the drug product as having a known or potential bioequivalence problem. A drug product so rated reflects a determination by FDA that an in vivo bioequivalence study is required.

(d) For certain drug products, bioavailability may be measured or bioequivalence may be demonstrated by evidence obtained in vitro in lieu of in vivo data. FDA shall waive the requirement for the submission of evidence obtained in vivo measuring the bioavailability or demonstrating the bioequivalence of the drug product if the drug product meets one of the following criteria:

(1) [Reserved]

(2) The drug product is in the same dosage form, but in a different strength, and is proportionally similar in its active and inactive ingredients to another drug product for which the same manufacturer has obtained approval and the conditions in paragraphs (d)(2)(i) through (d)(2)(iii) of this section are met:

(i) The bioavailability of this other drug product has been measured;

(ii) Both drug products meet an appropriate in vitro test approved by FDA; and

(iii) The applicant submits evidence showing that both drug products are proportionally similar in their active and inactive ingredients.

(iv) Paragraph (d) of this section does not apply to delayed release or extended release products.

(3) The drug product is, on the basis of scientific evidence submitted in the application, shown to meet an in vitro test that has been correlated with in vivo data.

(4) The drug product is a reformulated product that is identical, except for a different color, flavor, or preservative that could not affect the bioavailability of the reformulated product, to another drug product for which the same manufacturer has obtained approval and the following conditions are met:

(i) The bioavailability of the other product has been measured; and

(ii) Both drug products meet an appropriate in vitro test approved by FDA.

(e) FDA, for good cause, may waive a requirement for the submission of evidence of in vivo bioavailability or bioequivalence if waiver is compatible with the protection of the public health. For full new drug applications, FDA may defer a requirement for the submission of evidence of in vivo bioavailability if deferral is compatible with the protection of the public health.

(f) FDA, for good cause, may require evidence of in vivo bioavailability or bioequivalence for any drug product if the agency determines that any difference between the drug product and a listed drug may affect the bioavailability or bioequivalence of the drug product.

[57 FR 17998, Apr. 28, 1992, as amended at 67 FR 77673, Dec. 19, 2002]
The 15 cases that cite 21 C.F.R. § 320.22 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENViropharma Inc. v. Hamburg, 898 F. Supp. 2d 1 (D.D.C. 2012).
cites § 320.22 10×cited by 20 cases
Where it cites § 320.22
“21 (b) establishes, a default requirement that bioequivalence be demonstrated through in vivo testing, 14 subject to the waiver criteria set forth in 21 C.F.R. § 320.22 , which permits in vitro testing in limited circumstances.”
The case’s holding
Under deferential review, an agency interpretation that is a reasonable policy choice is upheld, and a drug manufacturer must show that the interpretation is something other than reasonable to prevail.
Later courts cite it for
“anything other than a reasonable policy choice for the fda to have made.” · 2 citing courts
2
GREENBristol-Myers Squibb Co. v. Shalala, 923 F. Supp. 212 (D.D.C. 1996).
cites § 320.22 6×cited by 41 cases
The case’s holding
A plaintiff fails to show irreparable harm where its economic loss from generic competition is under one percent of total sales and no evidence shows the competing product causes health harm.
Later courts cite it for
“there is a presumption in favor of the validity of the administrative action.” · 9 citing courts
3
GREENHill Dermaceuticals, Inc. v. Food & Drug Admin., 709 F.3d 44 (D.C. Cir. 2013).
cites § 320.22 2×cited by 85 cases
Where it cites § 320.22
“” 21 C.F.R. § 320.22 (b)(3). The FDA granted bioequivalence waivers for Identi’s body and scalp *47 oil under § 820.”
The case’s holding
In an APA case, a reviewing court should have before it neither more nor less information than the agency had when it made its decision.
Later courts cite it for
“it is black-letter administrative law that in an apa case, a reviewing court should have before it neither more nor less information than did the agency when it made its decision.” · 31 citing courts
4
GREENFisons Corp. v. Shalala, 860 F. Supp. 859 (D.D.C. 1994).
cites § 320.22 11×subsections: (b)cited by 3 cases
Where it cites § 320.22
“More specifically, Fisons claims that both (1) the FDA regulation permitting the waiver of certain testing for generic drug applications, 21 C.F.R. § 320.22 (b), and (2) FDA’s policy of waiving testing and approval of these generic drugs, are arbitrary, capricious, an abuse of…”
5
GREENViroPharma, Inc. v. Hamburg, 777 F. Supp. 2d 140 (D.D.C. 2011).
cites § 320.22 2×cited by 6 cases
Where it cites § 320.22
“21(b) sets forth a general requirement that bioequivalence be demonstrated through in vivo testing, unless the drug product meets one of the waiver criteria set forth in 21 C.F.R. § 320.22 . (Compl. ¶¶ 35-37.) The FDA, however, argues that there is no such “default requirement…”
Later courts cite it for
“harms to viropharma's ongoing business operations.” · 2 citing courts
6
GREENUnited States v. Baxter Healthcare Corp., 901 F.2d 1401 (7th Cir. 1990).
cites § 320.22 1×cited by 35 cases
Where it cites § 320.22
“See 21 C.F.R. § 320.22 (b). Thus, there would seem to be no issue concerning the bioavailability of the TRC products and the FDA-approved products.”
Later courts cite it for
“an administrative agency's interpretations of congressional acts, and even more so of its own regulations, are due great deference.” · 2 citing courts
7
GREENHill Dermaceuticals, Inc. v. U.S. Food & Drug Admin., 826 F. Supp. 2d 252 (D.D.C. 2011).
cites § 320.22 2×cited by 4 cases
Where it cites § 320.22
“” 21 C.F.R. § 320.22 (b)(3)(i)—(iii). Furthermore, each ANDA must include “the specifications necessary to ensure the identity, strength, quality, and purity of the drug substance .”
cites § 320.22 2×cited by 7 cases
Where it cites § 320.22
“” This is so, Dey argues, because ASI is administered by inhalation, and such being the case, 21 C.F.R. § 320.22 (b)(4) demonstrates as a matter of law that Dey’s ASI and “generic ASI” are bioequivalent.”
Later courts cite it for
“as a matter of law, 'any consensus which may exist regarding the safety or efficacy of the drug is not based upon adequate or well controlled studies” · 2 citing courts
9
GREENPharmadyne Labs., Inc. v. Kennedy, 466 F. Supp. 100 (D.N.J. 1979).
cites § 320.22 2×cited by 7 cases
Where it cites § 320.22
“For example, an applicant may waive evidence of in vivo bioavailability data, normally required for NDA or ANDA approval, 21 C.F.R. § 320.22 , where the drug product meets a number of conditions, one of which is that the drug contains no inactive ingredient known to…”
10
GREENSomerset Pharm., Inc. v. Shalala, 973 F. Supp. 443 (D. Del. 1997).
cites § 320.22 2×cited by 4 cases
Where it cites § 320.22
“21 C.F.R. § 320.22 . 1 In cases where “the in vivo bioavailability of bioequivalence of the drug product may be self-evident,” the drug application may be approved without demonstrating either bioavailability or bioequivalence.”
11
GREENSchering Corp. v. Sullivan, 782 F. Supp. 645 (D.D.C. 1992).
cites § 320.22 1×cited by 9 cases
Where it cites § 320.22
“, Exhibit 2, if 9; 21 C.F.R. § 320.22 (b)(4). Apart from its statutory challenge, Schering has not yet offered an adequate basis for challenging the support for or the application of that regulation in this case.”
Later courts cite it for
“reasonable and scientifically supported criterion, whether it chooses to do so on a case-by-case basis or through more general inferences about a category of drugs or dosage forms.” · 2 citing courts
cites § 320.22 2×cited by 3 cases
Where it cites § 320.22
“Second, G & W asserts that a triable issue exists as to whether Anucort is exempted from demonstrating bioequivalence under 21 C.F.R. § 320.22 (b)(2). This section waives the requirement for submission of evidence of bioavailability for “a topically applied preparation, e.”
13
GREENMidlothian Labs., LLC v. PAMLAB, LLC, 509 F. Supp. 2d 1065 (M.D. Ala. 2007).
cites § 320.22 1×cited by 3 cases
Where it cites § 320.22
“[49] 21 C.F.R. § 320.22 is entirely devoted to establishing "criteria for waiver of evidence of in vivo bioavailability or bioequivalence.”
14
GREENMidlothian Labs., L.L.C. v. Pamlab, L.L.C., 509 F. Supp. 2d 1065 (M.D. Ala. 2007).
cites § 320.22 1×cited by 5 cases
Where it cites § 320.22
“21 C.F.R. § 320.22 is entirely devoted to establishing "criteria for waiver of evidence of in vivo bioavailability or bioequivalence.”
Later courts cite it for
“must fail as a matter of course.” · 2 citing courts
15
NO FLAGViropharma Inc. v. Hamburg, No. 2010-1529 (D.D.C. Apr. 15, 2011).
cites § 320.22 2×cited by 0 cases
Where it cites § 320.22
“21(b) sets forth a general requirement that 2 bioequivalence be demonstrated through in vivo testing, unless the drug product meets one of the waiver criteria set forth in 21 C.F.R. § 320.22 . (Compl. ¶¶ 35-37.) The FDA, however, argues that there is no such “default requirement…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197919962013

One bar per year. Tallest: 3 cases in 2011. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.7M.D. Ala.2D.N.J.25th Cir.17th Cir.1D.C. Cir.1D. Del.1
By subsection
(b)1 case
Fisons Corp. v. Shalala, 860 F. Supp. 859 (D.D.C. 1994).“More specifically, Fisons claims that both (1) the FDA regulation permitting the waiver of certain testing for generic drug applications, 21 C.F.R. § 320.22 (b), and (2) FDA’s policy of waiving testing and approval of these generic drugs, are arbitrary, capricious, an abuse of…”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com